Skip to main content
. Author manuscript; available in PMC: 2018 Apr 17.
Published in final edited form as: Chem Res Toxicol. 2017 Mar 15;30(4):1017–1029. doi: 10.1021/acs.chemrestox.7b00025

Figure 3.

Figure 3

A. Daily Dose ≥ 50mg prediction (Safe/Not Safe) vs. FDA Hepatic ADR Categories.

There is a marked increase in the proportion of compounds that are dosed at greater than 50mg/day and have FDA drug label warnings associated with DILI adverse effects as illustrated in the “Warning and Precautions”, “Boxed Warning” and “Withdrawn” categories.

B. Daily Dose ≥ 50mg prediction (Safe/Not Safe) vs. FDA DILI severity assessment.

Similarly, there is a marked increase in the proportion of compounds that are dosed at greater than 50mg/day and have some type of DILI toxicity as illustrated in the “Non-severe DILI” and “Severe DILI” categories.